Key terms
About SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SEEL news
Mar 22
11:33am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 20
5:56am ET
Optimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Results
Mar 19
8:22am ET
Seelos Therapeutics provides update on top-line data of Phase 2/3 trial
Mar 15
4:25pm ET
Seelos Therapeutics files to sell 3.4M shares of common stock for holders
Feb 02
6:07am ET
Seelos Therapeutics files to sell 3.4M shares of common stock for holders
Jan 26
8:32am ET
Seelos Therapeutics to sell 3.4M shares at $1.175 in registered direct offering
Jan 23
8:30am ET
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Seelos Therapeutics (SEEL)
Jan 22
8:03am ET
Seelos receives FDA feedback on endpoints of Phase 2 SLS-002 trial in MDD
Jan 07
5:47am ET
BTIG Remains a Buy on Seelos Therapeutics (SEEL)
Jan 02
9:49am ET
Seelos Therapeutics (SEEL) Receives a Buy from BTIG
Jan 02
8:01am ET
ISS urges Seelos Therapeutics holders to vote ‘FOR’ all proposals at meeting
Dec 31
5:26am ET
Seelos Therapeutics (SEEL) Gets a Buy from BTIG
No recent press releases are available for SEEL
SEEL Financials
Key terms
Ad Feedback
SEEL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SEEL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
